Results 281 to 290 of about 114,065 (338)

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.

The Lancet Oncology, 2021
BACKGROUND Both continuous therapy with acalabrutinib and fixed-duration therapy with venetoclax-obinutuzumab are effective for previously untreated chronic lymphocytic leukaemia. We hypothesised that frontline time-limited, minimal residual disease (MRD)
M. Davids, B. Lampson, S. Tyekucheva, Zixu Wang, Jessica C Lowney, S. Pazienza, J. Montegaard, V. Patterson, M. Weinstock, J. Crombie, S. Ng, A. Kim, C. Jacobson, A. LaCasce, Philippe Armand, J. Arnason, D. Fisher, Jennifer R. Brown   +17 more
semanticscholar   +1 more source

Chronic lymphocytic leukaemia

Critical Reviews in Oncology/Hematology, 2016
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among the adults in the Western World. CLL (and the corresponding nodal entity small lymphocytic lymphoma, SLL) is classified as a lymphoproliferative disorder characterised by the relentless accumulation of mature B-lymphocytes showing a peculiar immunophenotype in the peripheral blood ...
Scarfò, Lydia, Ferreri, Andrés J. M, GHIA, PAOLO PROSPERO   +2 more
openaire   +2 more sources

Guideline for the treatment of chronic lymphocytic leukaemia

British Journal of Haematology, 2022
Department of Haematology, University Hospitals Dorset, Bournemouth, UK Department of Haematology, Aneurin Bevan University Health Board, Wales, UK Department of Haematology, Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust,
R. Walewska, N. Parry-Jones, T. Eyre, G. Follows, N. Martínez-Calle, H. McCarthy, Helen M Parry, P. Patten, J. Riches, P. Hillmen, A. Schuh   +10 more
semanticscholar   +1 more source

Chronic Lymphocytic Leukaemia

Medicine, 2000
Abstract Chronic lymphocytic leukaemia (CLL) results from neoplastic proliferation of a mature B lymphocyte. It is defined by a persistent lymphocytosis of more than 10 × 10 9 /litre and lymphoid infiltration of the bone marrow of at least 40%. With the use of immunological markers, it is possible to establish the diagnosis of CLL by B cell clonality,
Estella Matutes, Claire Dearden
openaire   +1 more source

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.

The Lancet Oncology, 2020
BACKGROUND Venetoclax plus obinutuzumab has been established as a fixed-duration treatment regimen for patients with chronic lymphocytic leukaemia.
O. Al‐Sawaf, Can Zhang, M. Tandon, Arijit Sinha, A. Fink, S. Robrecht, O. Samoylova, A. Liberati, J. Pinilla-Ibarz, Stephen Samuel Opat, L. Sivcheva, K. Le Dû, L. Fogliatto, C. Niemann, R. Weinkove, S. Robinson, T. Kipps, E. Tausch, W. Schary, M. Ritgen, C. Wendtner, K. Kreuzer, B. Eichhorst, S. Stilgenbauer, M. Hallek, K. Fischer   +25 more
semanticscholar   +1 more source

Chronic lymphocytic leukaemia

The Lancet
The last decade has seen remarkable progress in our understanding of disease biology of chronic lymphocytic leukaemia (CLL) and the development of novel targeted therapies. Randomised clinical trials have reported improved progression-free survival and overall survival with targeted therapies compared with chemoimmunotherapy, and thereby the role of ...
Nitin, Jain, William G, Wierda, Susan, O'Brien   +2 more
openaire   +3 more sources

Chronic lymphocytic leukaemia treatment

Blood Reviews, 1993
Advances in the understanding of the natural history and prognosis of chronic lymphocytic leukaemia (CLL) and the introduction of new drugs and strategies have renewed interest in the treatment of this disease. Clinical trials in patients stratified according to risk factors are useful to determine the efficacy of different treatments.
E, Montserrat, C, Rozman
openaire   +2 more sources

Lymphocyte Kinetics in Chronic Lymphocytic Leukaemia

British Journal of Haematology, 1970
51‐Chromium was used to study lymphocyte kinetics in patients with chronic lymphocytic leukaemia. Lymphocytes were found to equilibrate with a pool larger than that accounted for by blood volume and the blood lymphocyte count. Lymphocyte disappearance from the blood stream was exponential and complex, with an initial large rapid component and a smaller
J L, Spivak, S, Perry
openaire   +2 more sources

Chronic Lymphocytic Leukaemia with Binucleated Lymphocytes

Leukemia & Lymphoma, 1997
Chronic lymphocytic leukaemia (CLL) is a monoclonal proliferation usually involving B cells and composed of mature lymphoid cells. Distinct morphologic subtypes have been recognized according to lymphocyte size, nuclear:cytoplastic ratio and nucleolus.
I, Amouroux, H, Mossafa, O, Gentilhomme, R, Girot, G, Flandrin, X, Troussard   +5 more
openaire   +2 more sources

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

The Lancet Oncology, 2019
BACKGROUND Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown superior efficacy to chlorambucil monotherapy and are standard first-line treatments in chronic lymphocytic leukaemia.
C. Moreno, R. Greil, F. Demirkan, A. Tedeschi, B. Anz, L. Larratt, M. Šimkovič, O. Samoilova, J. Novak, D. Ben-yehuda, V. Strugov, D. Gill, J. Gribben, E. Hsu, C. Lih, Cathy Zhou, F. Clow, D. James, L. Styles, I. Flinn   +19 more
semanticscholar   +1 more source